Journal of Clinical Oncology
Articles in this Issue
Deep prostate-specific antigen (PSA) decline among early participants (pts) in LIBERTAS, a phase 3 study of apalutamide (APA) plus continuous versus intermittent androgen deprivation therapy (ADT) in metastatic castration-sensitive prostate cancer (mCSPC).
147 Background: LIBERTAS is investigating APA in combination with intermittent ADT as an ADT de-escalation strategy for patients with mCSPC. The objective...
Efficacy and safety of tislelizumab (T) combined with gemcitabine and cisplatin (GC) for patients with localized muscle-invasive bladder cancer (MIBC) after radical transurethral resection of bladder tumor/partial cystectomy: A prospective, phase II study.
784 Background: Transurethral resection of bladder tumor (TURBT) combined with concurrent chemoradiotherapy is the standard treatment for bladder preserva...
Frailty and adverse clinical outcomes in prostate cancer patients: An analysis from the RADICAL-PC cohort.
80 Background: As a disease of older individuals, prostate cancer (PC) may feature physical frailty. Most related studies are retrospective and focus on s...
Reflexive paired somatic and germline testing at time of medical oncology referral in mCSPC: Impact on timely treatment.
62 Background: Use of PARP inhibitors (PARPi) improves outcomes in patients with metastatic castrate-resistant prostate cancer (mCRPC) harboring germline...
PERSIAN trial: Early results from a randomized phase II trial testing apalutamide and stereotactic body radiation therapy for low-burden, metastatic, hormone-sensitive prostate cancer.
160 Background: Apalutamide+androgen deprivation therapy (ADT) showed to significantly improve overall survival in low and high volume metastatic hormone...
Evaluating an integrated germline polygenic and clinical risk model (P-CARE) specifically for aggressive prostate cancer.
237 Background: Polygenic scores are strongly associated with age at diagnosis of prostate cancer (PCa) but have not been clearly shown to discriminate be...
A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with <i>BRCA1/2</i> gene alterations (NePtune).
TPS430 Background: Patients with localized high-risk prostate cancer face an elevated risk of recurrence after radical prostatectomy (RP). Approximately 6...
Impact of pre-existing diabetes mellitus on acute care use in older patients with metastatic prostate cancer on androgen receptor signaling inhibitors.
119 Background: Androgen receptor signaling inhibitors (ARSIs) are mainstay treatments for metastatic prostate cancer. Hyperglycemia is a common side effe...
KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and targeted therapy combinations for advanced clear cell renal cell carcinoma (ccRCC).
440 Background: The phase 1/2 KEYMAKER-U03 Substudy 03B (NCT04626518) is being conducted to evaluate combination treatments for previously treated advance...
Racial disparities in secondary metastasis in patients with bladder cancer: A 5-year National Inpatient Sample study.
671 Background: Bladder cancer is one of the most common cancers globally, with significant variations in disease outcomes observed across racial groups....
Evaluating the efficacy of cabozantinib in patients with advanced renal cell carcinoma with bone metastasis: An open-label phase 2 study.
535 Background: Bone metastasis negatively impacts patients with advanced renal cell carcinoma (aRCC), leading to poor prognosis and quality of life. Some...
<i>FGD1</i> splice variants as predictors of brain and bone metastatic organotropism in clear cell renal cell carcinoma.
577 Background: Approximately 30% of patients with ccRCC present with metastatic disease (stage IV) and close to half of patients with stage III disease w...
Lenvatinib plus tislelizumab as first-line therapy for advanced fumarate hydratase-deficient renal cell carcinoma: A single-center, single-arm, phase II study.
443 Background: Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a rare and aggressive subtype of RCC with dismal prognosis. Although bevaciz...
The role of cytoreductive radical prostatectomy in the management of patients with metastatic hormone-sensitive prostate cancer.
157 Background: Cytoreductive radical prostatectomy (cRP) has emerged as an alternative treatment option to radiation therapy in men with low risk metasta...
Metastatic renal cell carcinoma (mRCC) primary refractory patients to first-line IO-TKI and IO-IO combinations (Meet-URO 33 analysis).
499 Background: Immune-combinations have become the cornerstone of the mRCC treatment scenario, but direct comparisons between the different first-line th...
Impact of site of metastatic involvement on IMDC classification in metastatic renal cell carcinoma patients treated with immunotherapy.
483 Background: The IMDC risk classification is indispensable for managing metastatic renal cell carcinoma (mRCC) patients (pts). However, it was not deve...
Regional and racial disparities in testicular cancer-related mortality among HIV/AIDS adults in the United States and Texas: A 21-year retrospective study (1999-2020).
624 Background: Men with HIV/AIDS have a significantly higher risk of developing germ cell tumors (GCT), with a notable increase in the incidence of testi...
Radiographic progression without PSA progression in advanced prostate cancer patients.
213 Background: Androgen Receptor Pathway Inhibitors (ARPIs) are frequently combined with Androgen Deprivation Therapy (ADT) to treat prostate cancer pati...
Effects of emerin dysregulation on the very-small-nuclear phenotype and neuronal differentiation and its association with a clinically aggressive subtype of prostate cancer.
207 Background: Circulating tumor cells (CTCs) with a very-small-nuclear (vsn) phenotype (i.e., vsnCTCs) in prostate cancer (PCa) represent a distinct sub...
Low-dose abiraterone in metastatic castration-resistant prostate cancer.
164 Background: Abiraterone acetate (AA) is a selective and irreversible inhibitor of CYP17 approved for locally advanced and metastatic prostate cancer....
The Man Van phase 2 results: Mobile targeted case finding for prostate cancer.
317 Background: Early intervention is potentially lifesaving in prostate cancer and is a major limitation of cancer outcomes with ethnicity and deprivatio...
Prevention, diagnosis, and management of penile cancer in the LGBTQ+ community: A systematic review and meta-analysis.
2 Background: Penile cancer is a rare but significant malignancy with unique prevention, diagnosis, and treatment challenges within the LGBTQ+ community....
EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).
664 Background: EV-302 /KEYNOTE-A39 (NCT04223856) demonstrated significant progression-free survival (PFS) and overall survival (OS) benefit with first-li...
Impact of loss of PRLHR on aneuploidy and initiation of bladder cancer.
854 Background: The question still remains for the presence of yet unknown genetic modifiers in the initiation and/or progression of bladder cancer (BC)....
Global and regional burden of kidney cancer: Analysis and future predictions based on GBD data from 1990 to 2021.
521 Background: Kidney cancer, as a common urological malignancy with poor prognosis, shows significant variations in incidence and mortality rates in dif...